Year: 2026
Type: article
Abstract: By inducing growth of the intestinal epithelium, the drug teduglutide, used for the treatment of short bowel syndrome-associated intestinal failure, could feasibly promote growth of pre-existing colonic neoplasms and incite the development of new ones. A baseline screen for colonic lesions and a 1-year follow-up have therefore been recommended, although an ongoing global prospective registry has, to date, shown no promotion of colonic neoplasms. Most recently, there have been reports of patients developing upper intestinal polyps while on the drug, including ones with malignant potential. To ensure patient safety, the Committee overseeing the global registry therefore recommends that monitoring strategies be updated to include screening for small intestinal lesions as well.
Source: npj gut and liver.
Institutions: Université Paris Cité, Hôpital Beaujon, University of Toronto, Toronto General Hospital, Fundacion Favaloro Hospital Universitario, Favaloro Foundation, Rigshospitalet, University Hospital Schleswig-Holstein, Asklepios Klinik St. Georg, Charité - Universitätsmedizin Berlin, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, NYU Langone Health, Tufts University, Tufts Medical Center
Language: English
Subfield: Nutrition and Dietetics
Field: Nursing
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,790
OpenAlex ID: W7118357066